FHIT Suppresses Epithelial-Mesenchymal Transition (EMT) and Metastasis in Lung Cancer through Modulation of MicroRNAs

English version České info

Although Fragile Histidine Triad (FHIT) is known as a potential tumor suppressor gene in terms of tumor initiation and progression, the role of FHIT in the metastatic process is not well characterized. Here it is shown that FHIT reduces the motility and invasiveness of lung cancer cells in vitro and ability to metastasize in vivo, at least partially through the miR-30c-mediated suppression of EMT, a critical process during tumor metastasis. This study provides new insights into the role of FHIT and a FHIT-activated miRNA, miR-30c, as crucial modulators in lung metastasis.

Vyšlo v časopise: FHIT Suppresses Epithelial-Mesenchymal Transition (EMT) and Metastasis in Lung Cancer through Modulation of MicroRNAs. PLoS Genet 10(10): e32767. doi:10.1371/journal.pgen.1004652
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1004652

Souhrn

Zdroje

1. ChambersAF, GroomAC, MacDonaldCM (2002) Dissemination and growth of cancer cells in metastatic sites. Nature Rev Cancer 2: 563–572.

2. FolkmanJ (2002) The role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15–18.

3. PolyakK, WeinbergRA (2009) Transition between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Rev Cancer 9: 265–273.

4. ManiSA, GuoW, LiaoMJ, EatonEN, AyyananA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 16: 704–715.

5. KalluriR (2009) EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119: 1417–1419.

6. ZavadilJ, BottingerEP (2005) TGF-beta and epithelial-to mesenchymal transitions. Oncogene 29: 5764–5774.

7. GregoryPA, BertAG, PatersonEL, BarrySC, TsykinA, et al. (2008) The miR-200 family and miR-205 regulate epithelial to meshenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593–601.

8. SiemensH, JackstadtR, HuntenS, KallerM, MenssenA, et al. (2010) miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10: 4256–4271.

9. EdmondsMD, HurstDR, VaidyaKS, StaffordLJ, ChenD, et al. (2009) Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer 125: 1778–1785.

10. ZhangJG, WangJJ, ZhaoF, LiuQ, JiangK, et al. (2010) MicroRNA-21(miR-21) represses tumor suppressor PTEN and promote growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 411: 846–852.

11. SampsonVB, RongNH, HanJ, YangQ, ArisV, et al. (2007) MicroRNA Let-7a down-regulates MYC and reverts MYC-induced growth in burkitt lymphoma cells. Cancer Res 67: 9762–9770.

12. LeeYS, DuttaA (2007) The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025–1030.

13. LaganaA, RussoF, SismeiroC, GiuqnoR, PuvirentiA, et al. (2010) Variability in the incidence of miRNAs and genes in fragile sites and the role of repeats and CpG islands in the distribution of genetic material. PLos One 5: e11166.

14. StarczynowskiDT, MorinR, McPhersonA, LamJ, ChariR, et al. (2011) Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 117: 595–607.

15. OhtaM, InoueH, CotticelliMG, KasturyK, BaffaR, et al. (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t (3; 8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587–597.

16. SozziG, VeroneseML, NegriniM, BaffaR, CotticelliMG, et al. (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85: 17–26.

17. NegriniM, MonacoC, VorechovskyI, OhtaM, DruckT, et al. (1996) The FHIT gene at 3p14.2 is abnormal in breast carcinoma. Cancer Res 56: 3173–3179.

18. SongX, TianZ, WangS, PengZ, FengJ (2010) Restoration of fragile histidine triad (FHIT) expression inhibits cell growth and induces apoptosis in cutaneous T-cell lymphoma cell line. Cancer Invest 28: 1019–1023.

19. JoannesA, BonnometA, BindelsS, PoletteM, GillesC, et al. (2010) Fhit regulates invasion of lung tumor cells. Oncogene 29: 1203–1213.

20. JoannesA, GreletS, DucaL, GillesC, KileztkyC, et al. (2014) Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells. Mol Cancer Res 12: 775–783.

21. XuJ, LamouilleS, DerynckR (2009) TGF-β-induced epithelial to mesenchymal transition. Cell Res 19: 156–172.

22. KatsunoY, LamouillesS, DerynckR (2013) TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25: 76–84.

23. Antonov AV, Knight RA, Melino G, Barlev NA, Tsvetkov PO (2012). MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets. Cell Death Differ. Doi:10.1038/cdd.2012.137.

24. GyorffyB, LanczkyA, EklundAC, DenkertC, BudcziesJ, et al. (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1.809 patients. Breast Cancer Res Treatment 123: 725–731.

25. HuG, ChongRA, YangQ, WeiY, BlancoMA, et al. (2009) MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15: 9–20.

26. HristovAC, CopeL, ReyesMD, SinghM, Lacobuzio-DonahueC, et al. (2009) HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol 22: 43–49.

27. DumonKR, IshiiH, FongLY, ZanesiN, FidanzaV, et al. (2001) FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 98: 3346–3351.

28. ToledoG, SolaJJ, LozanoMD, SoriaE, PardoJ (2004) Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small- cell lung cancer. Mod Pathol 17: 440–448.

29. BekarA, CecenerG, TuncaB, GulerG, EgeliU, et al. (2007) Investigation of mutations and expression of the FHIT gene in Turkish patients with brain metastases derived from non-small cell lung cancer. Tumori 93: 604–607.

30. ZhaoP, LiXY, ChenLZ (2002) Loss of fragile histidine triad expression and metastasis in breast cancer. Ai Zheng 21: 668–670.

31. YuF, DengH, YaoH, LiuQ, SuF, et al. (2010) Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 29: 4194–4204.

32. Bochhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, et al.. (2013). MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun.4, Article number 1393.

33. BudhuA, JiaHL, ForquesM, LiuCG, GoldsteinD, et al. (2008) Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47: 897–907.

34. JoqlekarKV, PatilD, JoqlekarVM, RaoGV, ReddyDN, et al. (2009) The miR-30 family microRNAs confer epithelial phenotype to human pancreatic cells. Islets 1: 137–147.

35. ZhangJ, ZhangH, LiuJ, TuX, ZhangY, et al. (2012) miR-30 inhibits TGF-β1-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1. Biochem Biophys Res Commun 417: 1100–1105.

36. MinnAJ, GuptaGP, SiegelPM, BosPD, ShuW, et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436: 518–524.